Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas

NCT00185965 is registered in ClinicalTrials.gov with Ronald Levy as lead sponsor.

NCT NCT00185965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00185965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas
Lead sponsor
Ronald Levy
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2004
Completion date
March 31, 2010
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mycosis fungoides, non-hodgkin lymphoma